SEARCH

SEARCH BY CITATION

References

  • 1
    Yates DY, Peters MJ, Keatings V, Thomas PS, Barnes PJ. Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma. Eur Respir J 1995; 8: 18471851.
  • 2
    Clay MM, Newman SP, Clarke SW, Pavia D, Lennard Jones T. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983; ii: 592594.
  • 3
    Newnham DM, Lipworth DJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (Ventstream). Thorax 1994; 49: 762770.
  • 4
    Cushley MJ, Lewis RA, Tattersfield AE. Comparison of three techniques of inhalation in the airway response to terbutaline. Thorax 1983; 38: 908913.
  • 5
    Lipworth BJ, Clark BJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 1997; 52: 10361039.
  • 6
    Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34: 311315.
  • 7
    Tomlinson HS, Corlett SA, Chrystyn H. Effect of dose on the relative lung bioavailability of salbutamol. J Aerosol Med 1995; 8: P193.
  • 8
    Chrystyn H, Allen MB, Corlett SA, Tomlinson HS. Simultaneous measurement of pharmacodynamic and pharmacokinetic parameters which can be used to evaluate the equivalence of inhaled salbutamol. Am J Respir Crit Care Med 1998; 157: A636.
  • 9
    Silkstone VL, Corlett SA, Chrystyn H. Relative bioavailablity of salbutamol to the lung when administartion is prolonged. Br J Clin Pharmacol 2000; 50: 281284.
  • 10
    O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52(Suppl 2): S31S44.
  • 11
    Zainudin BM, Bibbiscombe M, Tolfree SEJ, Short M, Spiro SG. Comparison of bronchodilator response and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45: 469473.
  • 12
    Johnson MA, Newman SP, Bloom R, Talaee N, Clarke SW. Delivery of albuterol and ipratropiom bromide from two nebulized systems in chronic stable asthma. Efficacy and pulmonary deposition. Chest 1989; 96: 110.
  • 13
    Borgstrom L, Newman SP, Weisz AWB, Moren F. Pulmonary deposition of inhaled terbutaline: Comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992; 81: 753755.
  • 14
    Niven RM, Brain JD. Some functional aspects of air jet nebulisers. Int J Pharm 1994; 104: 7385.
  • 15
    Faurisson F, Dessanges JF, Grimfield A, et al. Nebuliser performance. AFCM study. Respiration 1995; 62: 1318.
  • 16
    Meurs MF. The national use of nebulisers in clinical practice. Eur Respir J 1997; 44: 189197.
  • 17
    Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhaler methods and spacer devices. Thorax 1994; 49: 549553.
  • 18
    Hindle M, Newton DAG, Chrystyn H. Dry powder inhalers are bioequivalent to metered dose inhalers: a study using a new urinary albuterol (salbutamol) assay technique. Chest 1995; 107: 629633.
  • 19
    Payne N, Beard S, Brocklebank D, Ram F, Wright J, Taylor R. Clinical and cost effectiveness of inhaler devices for children with chronic asthma. http://server1.nice.org.uk/nice-web/pdf/asthma.pdf.